Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects

por Hyland, Elizabeth, Mant, Tim, Vlachos, Pantelis, Attkins, Neil, Ullmann, Martin, Roy, Sanjeev, Wagner, Volker
Publicado 2016

Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial

por Wynne, Chris, Schwabe, Christian, Vincent, Emmanuelle, Schueler, Armin, Ryding, Janka, Ullmann, Martin, Ghori, Vishal, Kanceva, Radmila, Stahl, Michael
Publicado 2020